Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis

Yun Hou; Chung Heon Ryu; Jin Ae Jun; Seong Muk Kim; Chang Hyun Jeong; Sin Soo Jeun

doi:10.1016/j.jneuroim.2014.06.001

Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis

Yun Hou
, Chung Heon Ryu
, Jin Ae Jun
, Seong Muk Kim
, Chang Hyun Jeong
, Sin Soo Jeun

Department of Neurosurgery

The Catholic University of Korea
Catholic Univ. of Korea Coll. Med.

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

We previously demonstrated that interferon β (IFN-β)-secreting mesenchymal stem cells (MSCs-IFN-β) strongly reduced the clinical severity of experimental autoimmune encephalomyelitis (EAE), compared with MSCs alone. Recently, minocycline ameliorates the clinical severity of multiple sclerosis (MS). Herein, we evaluated the effects of a combined treatment of MSCs-IFN-β and minocycline on EAE mice. The combined treatment significantly alleviated the clinical severity mainly by maintaining the integrity of blood-spinal cord barrier, in a manner likely involving inhibition of microvascular disruption, matrix metalloproteinases, neuroinflammation, and enhancement of immunomodulatory effects. Therefore, this combined treatment has the potential to improve the functional recovery of patients with MS.

Original language	English
Pages (from-to)	20-27
Number of pages	8
Journal	Journal of Neuroimmunology
Volume	274
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2014.06.001
State	Published - 2014

Bibliographical note

Funding Information:
This study was supported by grants from the Korea Health Technology R&D Project ( A110330 , HI09C1555 ), Ministry of Health & Welfare, Republic of Korea and Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea . The Catholic MASTER Cells supplied by Catholic Institute of Cell Therapy (CIC, Seoul, Korea) were derived from human bone marrow donated by healthy donors after informed consent.

Keywords

Blood-spinal cord barrier disruption
Experimental autoimmune encephalomyelitis
IFN-β-secreting mesenchymal stem cells
Minocycline
Multiple sclerosis
Tight junctions

Access to Document

10.1016/j.jneuroim.2014.06.001

Cite this

@article{91c4213bf5e846e89902b9e36a2c0b09,

title = "Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis",

abstract = "We previously demonstrated that interferon β (IFN-β)-secreting mesenchymal stem cells (MSCs-IFN-β) strongly reduced the clinical severity of experimental autoimmune encephalomyelitis (EAE), compared with MSCs alone. Recently, minocycline ameliorates the clinical severity of multiple sclerosis (MS). Herein, we evaluated the effects of a combined treatment of MSCs-IFN-β and minocycline on EAE mice. The combined treatment significantly alleviated the clinical severity mainly by maintaining the integrity of blood-spinal cord barrier, in a manner likely involving inhibition of microvascular disruption, matrix metalloproteinases, neuroinflammation, and enhancement of immunomodulatory effects. Therefore, this combined treatment has the potential to improve the functional recovery of patients with MS.",

keywords = "Blood-spinal cord barrier disruption, Experimental autoimmune encephalomyelitis, IFN-β-secreting mesenchymal stem cells, Minocycline, Multiple sclerosis, Tight junctions",

author = "Yun Hou and \{Heon Ryu\}, Chung and Jun, \{Jin Ae\} and Kim, \{Seong Muk\} and Jeong, \{Chang Hyun\} and Jeun, \{Sin Soo\}",

note = "Funding Information: This study was supported by grants from the Korea Health Technology R\&D Project ( A110330 , HI09C1555 ), Ministry of Health \& Welfare, Republic of Korea and Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea . The Catholic MASTER Cells supplied by Catholic Institute of Cell Therapy (CIC, Seoul, Korea) were derived from human bone marrow donated by healthy donors after informed consent.",

year = "2014",

doi = "10.1016/j.jneuroim.2014.06.001",

language = "English",

volume = "274",

pages = "20--27",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier B.V.",

number = "1-2",

}

TY - JOUR

T1 - Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis

AU - Hou, Yun

AU - Heon Ryu, Chung

AU - Jun, Jin Ae

AU - Kim, Seong Muk

AU - Jeong, Chang Hyun

AU - Jeun, Sin Soo

N1 - Funding Information: This study was supported by grants from the Korea Health Technology R&D Project ( A110330 , HI09C1555 ), Ministry of Health & Welfare, Republic of Korea and Research Fund of Seoul St. Mary's Hospital, The Catholic University of Korea . The Catholic MASTER Cells supplied by Catholic Institute of Cell Therapy (CIC, Seoul, Korea) were derived from human bone marrow donated by healthy donors after informed consent.

PY - 2014

Y1 - 2014

N2 - We previously demonstrated that interferon β (IFN-β)-secreting mesenchymal stem cells (MSCs-IFN-β) strongly reduced the clinical severity of experimental autoimmune encephalomyelitis (EAE), compared with MSCs alone. Recently, minocycline ameliorates the clinical severity of multiple sclerosis (MS). Herein, we evaluated the effects of a combined treatment of MSCs-IFN-β and minocycline on EAE mice. The combined treatment significantly alleviated the clinical severity mainly by maintaining the integrity of blood-spinal cord barrier, in a manner likely involving inhibition of microvascular disruption, matrix metalloproteinases, neuroinflammation, and enhancement of immunomodulatory effects. Therefore, this combined treatment has the potential to improve the functional recovery of patients with MS.

AB - We previously demonstrated that interferon β (IFN-β)-secreting mesenchymal stem cells (MSCs-IFN-β) strongly reduced the clinical severity of experimental autoimmune encephalomyelitis (EAE), compared with MSCs alone. Recently, minocycline ameliorates the clinical severity of multiple sclerosis (MS). Herein, we evaluated the effects of a combined treatment of MSCs-IFN-β and minocycline on EAE mice. The combined treatment significantly alleviated the clinical severity mainly by maintaining the integrity of blood-spinal cord barrier, in a manner likely involving inhibition of microvascular disruption, matrix metalloproteinases, neuroinflammation, and enhancement of immunomodulatory effects. Therefore, this combined treatment has the potential to improve the functional recovery of patients with MS.

KW - Blood-spinal cord barrier disruption

KW - Experimental autoimmune encephalomyelitis

KW - IFN-β-secreting mesenchymal stem cells

KW - Minocycline

KW - Multiple sclerosis

KW - Tight junctions

UR - https://www.scopus.com/pages/publications/84908698457

U2 - 10.1016/j.jneuroim.2014.06.001

DO - 10.1016/j.jneuroim.2014.06.001

M3 - Article

C2 - 25005115

AN - SCOPUS:84908698457

SN - 0165-5728

VL - 274

SP - 20

EP - 27

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this